Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors
- 15 June 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (12) , 3048-3052
- https://doi.org/10.1016/j.bmcl.2005.04.028
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Glucagon-like peptide-1: physiology and therapeutic potentialCurrent Opinion in Endocrinology, Diabetes and Obesity, 2005
- Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugsExpert Opinion on Investigational Drugs, 2005
- Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitusCurrent Opinion in Pharmacology, 2004
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs, 2004
- Therapeutic Strategies Based on Glucagon-Like Peptide 1Diabetes, 2004
- Dipeptidyl Peptidase IV Inhibitors for the Treatment of DiabetesJournal of Medicinal Chemistry, 2004
- Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2004
- Gut peptides in the treatment of diabetes mellitusExpert Opinion on Investigational Drugs, 2004
- Glucagon-like peptide-1 receptor is involved in learning and neuroprotectionNature Medicine, 2003